- Home
- ITRG vs MAIA Comparison
ITRG vs MAIA Comparison
Compare ITRG & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ITRG | MAIA |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Precious Metals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 744.6M | 49.3M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | ITRG | MAIA |
|---|---|---|
| Price | $4.30 | $2.16 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.13 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 622.1K |
| Earning Date | 11-12-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.08 | N/A |
| Revenue | ★ $219,125,000.00 | N/A |
| Revenue This Year | $965.93 | N/A |
| Revenue Next Year | $9.39 | N/A |
| P/E Ratio | $52.25 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.79 | $0.87 |
| 52 Week High | $4.69 | $2.74 |
Technical Indicators
Market Signals| Indicator | ITRG | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 58.41 | 74.91 |
| Support Level | $3.88 | $1.49 |
| Resistance Level | $4.57 | $1.71 |
| Average True Range (ATR) | 0.22 | 0.16 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 69.14 | 99.99 |
Price Performance
Historical ComparisonAbout ITRG Integra Resources Corp.
Integra Resources Corp is a precious metals exploration and development company in the Great Basin of the Western USA. Integra is currently focused on advancing its two flagship oxide heap leach projects: the past-producing DeLamar Project located in southwestern Idaho and the Nevada North Project, comprised of the Wildcat and Mountain View deposits, located in northwestern Nevada. The company also holds a portfolio of prospective early-stage exploration projects in Idaho, Nevada, and Arizona.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.